InvestorsHub Logo
Post# of 252254
Next 10
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

Re: DewDiligence post# 144017

Tuesday, 06/19/2012 5:00:42 AM

Tuesday, June 19, 2012 5:00:42 AM

Post# of 252254
ORR in ITT population is 22.9% in the FDA analysis, and in the 'truly' unmet need (patients unresponsive or intolerant to approved agents) is above 20% in all subgroups, so I think the efficacy demand is met but seems it may not justify the risk for cardiotox in the FDA's view and chances are quite high they will want more data.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.